Formulation and Evaluation of 3D Printed Pregabalin Tablets Targeted For Neuropathic Pain By Qbd Approach For Personalized Medicine

The 3D printing technology has been newly employed in the design and formulation of different dosage forms with the aim of formulation and evaluation of 3D printed Pregabalin tablets for the treatment of neuropathic pain by QbD approach. Drug (Pregabalin) together with other excipients, were mixed and extruded into filaments by hot melt extrusion. Then with the help of fused deposition modeling these obtained filaments were printed into tablets. Due to the use of different polymers in the printed formulation, different release profiles for the 3D printed tablets were obtained. Drug release characteristics, change the infill or the size of the printed tablets, allowing the personalization of the tablets. Filaments and tablets were characterized by means of Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), X- RAY powder diffraction (XRPD), and thermo gravimetric analysis (TGA). The results showed that after printing, the processing condition did not have a significant impact on the stability of the drug and the crystalline nature of the drug remained. Fused deposition modeling (FDM) 3D printing makes it possible not only to formulate 3D printing Pregabalin tablets for the treatment of neuropathic pain but also to modify the potential of additive manufacturing in the development of personalized dose medicines. This study presents novel formulations containing Pregabalin for prevention of neuropathic pain and investigates 3D printing technology for personalized production of oral solid dosage from enabling adjustable dose as well as drug release properties.